Monitoring Report: GLP-1 RA Prescribing Trends - September 2026 Data

Prescribing of GLP-1-based medications in US EHR data rose 7.0% from June to September 2026, totaling 23,616,330 prescriptions across 4,458,532 patients.

• Why it matters: Updated US real-world prescribing and patient-characterization data are limited for GLP-1 RAs used for type 2 diabetes and weight management, including how access changes may shift use.
• What they did: Truveta EHR data identified 4,458,532 people prescribed GLP-1-based medications from January 01, 2019 to September 30, 2026, tracking volumes and characteristics by medication and FDA-labeled use.
• The result: AOM prescribing increased 12.2% (+0.38 percentage points) from June to September 2026, driven largely by tirzepatide (+16.9%) and a >112.2% rise in orforglipron; first-time AOM prescribing was +3.7% in September vs June.